跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

934380

Sigma-Aldrich

1-Piperazinecarboxylic acid, 4-(4-piperidinyl)-, 1,1-dimethylethyl ester

≥98%

别名:

1-Boc-4-(piperidin-4-yl)-piperazine, 1,1-Dimethylethyl 4-(4-piperidinyl)-1-piperazinecarboxylate (ACI), 1-tert-Butoxycarbonyl-4-(piperidin-4-yl)piperazine, 1-Boc-4-(piperidin-4-yl)piperazine, 2-Methylpropan-2-yl 4-(piperidin-4-yl)piperazine-1-carboxylate, 4-(Piperidin-4-yl)piperazine-1-carboxylic acid tert-butyl ester, tert-Butyl 4-(4-piperidyl)piperazine-1-carboxylate, tert-Butyl 4-(piperidin-4-yl)piperazine-1-carboxylate

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C14H27N3O2
CAS号:
205059-24-1
分子量:
269.38
MDL號碼:
MFCD04974009
分類程式碼代碼:
12352108
NACRES:
NA.21

品質等級

100

化驗

≥98%

形狀

powder

儲存溫度

2-8°C

SMILES 字串

CC(C)(C)OC(=O)N1CCN(CC1)C2CCNCC2

InChI

1S/C14H27N3O2/c1-14(2,3)19-13(18)17-10-8-16(9-11-17)12-4-6-15-7-5-12/h12,15H,4-11H2,1-3H3

InChI 密鑰

IMFPSYLOYADSFR-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

應用

A semi-flexible linker useful for PROTAC development for targeted protein degradation. Incorporation of rigidity into the linker region of PROTACs may impact degradation kinetics as well as ADMET properties of PROTACs.

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks

法律資訊

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000266587
0000246842
0000246842
0000266587

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jingwei Shao et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(20), e2102555-e2102555 (2021-08-17)
DNA-binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand-binding
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门